Anti-infective Antibacterial Compounds against Mycobacterium tuberculosis and other Mycobacterium Species
Opportunity
Available for Licensing
IP Status
PCT Patent Pending: WO 2017/184947 A1 (Recent Notice of Allowance)
Inventors
Richard Slayden
Steven Sucheck
Sandeep Thanna
At A Glance
Researchers at Colorado State University in collaboration with the University of Toledo have developed new antimicrobial agents that are effective against human and veterinary pathogens, particularly acid-fast organisms such as Mycobacterium tuberculosis. The compounds show improved efficacy and activity well below toxicity to human monocytic cells.
Background
Mycobacterium tuberculosis is an acid-fast gram-positive bacterium that causes tuberculosis (TB). TB ranks first for the number of deaths in humans caused by an infectious agent. It has been difficult to eradicate TB even though the infection is treatable. Treatment for TB takes at least 6 months and, sometimes, up to 2 years. Often, patients do not comply with the entire treatment regimen due to the high numbers of pills per day and the associated side effects. The discontinuation of treatment results in drug resistance. Therefore, there is an immediate need for drugs with improved efficacy and reduced toxicity.
Benefits
- Unique composition and possess unique chemistry in preparation of derivatives
- Exhibit good activity to toxicity ratio (active at concentrations 20-fold lower than toxicity)
- High potency (MIC = 0.2 – 0.44 µM) against Mycobacterium tuberculosis strains resistant to Isoniazid, Rifampicin and fluoroquinolones. This suggests activity against multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains
Applications
- Treatment of drug-resistant tuberculosis
- Treatment of other infections resulting from other Mycobacterium species
Publications
Thanna S et al., Synthesis and evaluation of new 2-aminothiophenes against Mycobacterium tuberculosis. Organic & Biomolecular Chemistry, 2016, 14(25):6119-6133
Last updated: April 2020